26
total announcements
543960.BO · 15 min delayed
Concord Biotech Ltd
Concord Biotech Ltd has successfully conducted an earnings call for the second quarter and half year ended September 30, 2026, and the audio recording is available on the company's website.
Concord Biotech Ltd
Concord Biotech Ltd has announced its schedule of analyst/institutional investor meetings under SEBI regulations, to be held on 3rd and 4th November 2026 in Singapore.
Concord Biotech Ltd
Concord Biotech Ltd has announced its unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026. The company has also published a notice regarding the loss of share certificates and the issue of duplicate share certificates.
Concord Biotech Ltd
Concord Biotech Ltd has announced its unaudited standalone and consolidated financial results for the second quarter and half year ended on September 30, 2026, showing a broad-based growth across all product categories and geographies, with a 26% increase in revenue and 25% increase in EBITDA.
Concord Biotech Ltd
Concord Biotech Ltd has fixed November 04, 2026 as the record date for issuance of bonus equity shares in the ratio of 1:1.
Concord Biotech Ltd
Concord Biotech Ltd has announced unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2026, along with the Limited Review Reports issued by M/s. BSR & Co. LLP, the Statutory Auditors. The company has also fixed November 4, 2026, as the record date for the issue of bonus equity shares.
Concord Biotech Ltd
Concord Biotech Ltd has announced its unaudited financial results for the quarter and half year ended September 30, 2026, and has fixed November 4, 2026 as the record date for the issue of bonus equity shares. The company has also reconstituted its committees of the board.
Concord Biotech Ltd
Concord Biotech Ltd has submitted the Scrutinizer's report and voting results of the Postal Ballot dated September 23, 2026, which has been passed with requisite majority. The company has increased its authorized share capital and issued bonus equity shares.
Concord Biotech Ltd
Concord Biotech Ltd has scheduled an earnings call to discuss its unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2026.
Concord Biotech Ltd
Concord Biotech Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 to consider and approve unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026 along with Limited Review Report thereon.
Concord Biotech Ltd
Concord Biotech Ltd has issued a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended September 30, 2026.
Concord Biotech Ltd
Concord Biotech Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter and half year ended September 30, 2026.
Concord Biotech Ltd
Concord Biotech Ltd has published a newspaper advertisement for a Notice of Postal Ballot dated September 23, 2026, and Remote E-Voting Information, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Concord Biotech Ltd
Concord Biotech Ltd has announced a Postal Ballot Notice to increase its authorized share capital from Rs. 11,00,00,000 to Rs. 22,00,00,000, with voting to commence on September 25, 2026, and end on October 24, 2026.
Concord Biotech Ltd
Concord Biotech Ltd has approved the issuance of bonus shares in the ratio of 1:1 and an increase in the authorized share capital from Rs. 11,00,00,000 to Rs. 22,00,00,000, subject to shareholder approval.
Concord Biotech Ltd
Concord Biotech Ltd has informed that its officials will be attending an investor conference on August 26, 2026, in Ahmedabad.
Concord Biotech Ltd
Concord Biotech Ltd reported a strong start to FY27 with Q1 FY27 revenues of INR257 crores, reflecting a 26% year-on-year growth. The company encountered challenges in FY26 but remains confident of sustaining momentum in FY27 due to its long-term growth strategy, niche capabilities, and leadership position in key molecules.
Concord Biotech Ltd
Concord Biotech Ltd has hosted the audio recording of its Q1 FY27 earnings call on its website.
Concord Biotech Ltd
Concord Biotech Ltd has released its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, showing a broad-based growth across all product categories, with exports growing by ~46% for Q1FY27 (Y-o-Y). The company has also witnessed an increase in wallet share among existing customers, addition of new products, and a robust product pipeline. The financial highlights include a revenue growth of +26%, EBITDA growth of +34%, and PAT growth of +31%.
Concord Biotech Ltd
Concord Biotech Ltd has announced the voting results of its 41st Annual General Meeting (AGM), where all resolutions were passed with requisite majority. The company has declared a dividend and appointed a new director.